Vitamin D and Health

Table 47: Meta-analysis of genetic studies on multiple sclerosis risk
Study Methods Results Author’s conclusions
Huang & Xie
(2012)
Tizaoui et al
(2014)
Selection criteria:
Inclusion: Studies that evaluated VDR polymorphisms & risk
of MS; case-control design based on unrelated individuals;
and sufficient data for genotype distributions in both cases
and controls.
Exclusion: No control; no usable data reported
Selection criteria:
Inclusion: Case control studies that reported the number of
individual genotypes and/or alleles for VDR polymorphisms
in cases and controls. Each study had disease outcome
definitions that followed accepted diagnostic guidelines.
Exclusion: Cross-sectional studies, size of cases and controls
not reported.
Outcome measure
The association of VDR polymorphisms with MS risk.
11 case-control studies (2599 cases & 2816 controls). 2 studies in
Asian & 9 in white populations.
Apa-I polymorphism (rs7975232) 4 studies (599 cases & 878
controls)
Dominant model: OR=0.71 (95% CI, 0.46-1.12); p=0.14
Recessive model: OR=1.09 (95% CI, 0.85-1.38); p=0.51
Homozygote model: OR=0.72 (95% CI, 0.39-1.36); p=0.32
Bsm-I polymorphism (rs1544410) 3 studies (352 cases & 582
controls)
Dominant model: OR=0.81 (95% CI, 0.36-1.80); p=0.60
Recessive model: OR=1.17 (95% CI, 0.83-1.64); p=0.38
Homozygote model: OR=1.48 (95% CI, 0.90-2.45); p=0.12
Fok-I polymorphism (rs10735810) 6 studies (1775 cases &1830
controls)
Dominant model: OR=0.99 (95% CI, 0.87-1.14); p=0.93
Recessive model: OR=0.89 (95% CI, 0.74-1.07); p=0.21
Homozygote model: OR=0.90 (95% CI, 0.74-1.11); p=0.33
Taq-I polymorphism (rs731236) 8 studies (2472 cases & 2446
controls)
Dominant model: OR=1.12 (95% CI, 1.00-1.26); p=0.06
Recessive model: OR=1.03 (95% CI, 0.88-1.20); p=0.74
Homozygote model: OR=1.04 (95% CI, 0.78-1.38); p=0.80
13 case-control studies (n=3300 cases & 3194 controls)
TaqI polymorphism: 11 studies (3011 cases & 2810 controls)
Homozygous model: OR=0.90 (95% CI, 0.78-1.04); p=0.163
BsmI polymorphisms: 3 studies (247 cases & 276 controls)
Codominant model: OR=0.85 (95% CI, 0.27-2.66)
Allele contrast model: OR=0.91 (95%CI, 0.51-1.64); p=0.771
ApaI polymorphism: 5 studies (858 cases & 1097 controls)
Codominant model:
OR1=0.83 (95% CI, 0.64-1.08); p=0.016
OR2=1.34 (95% CI, 0.85-2.27); p=0.19
OR3=1.45 (95% CI, 1.04-2.2.08); p=0.03
FokI polymorphism: 7 studies (1989 cases & 1872 controls)
Recessive model: OR=1.03 (95% CI, 0.86-1.24); p=0.074
The VDR Apa-I, BSM-I, Fok-I and
Taq-I polymorphisms not associated
with MS risk.
No significant association between
TaqI and BsmI polymorphisms and
multiple sclerosis risk
Significant association between the
AA ApaI & FF FokI polymorphisms
and multiple sclerosis.
231